Invitation to industry sessions

The invitation leaflets of the industry sessions of the 32nd ECNP Congress are published below.

Saturday 7 September

C.01 – Bipolar disorder & pregnancy

Satellite Symposium
C.01 – Bipolar disorder & pregnancy 
12.15-13.45, Auditorium 15
Educational financial support provided by Sanofi




 
C.02 – Managing adult ADHD patients with psychiatric comorbidity

Satellite Symposium
C.02 – Managing adult ADHD patients with psychiatric comorbidity
12.15-13.45, Room C1
Educational financial support provided by Takeda/Global Medical Education

 

   
 C.03

Satellite Symposium
C.03 – Patient centricity in depression: how to measure what is most important?
12.15-13.45, Room C4
Educational financial support provided by H. Lundbeck A/S

 

   
 C.04

Satellite Symposium
C.04 – Improving outcomes of schizophrenia with long-acting antipsychotic treatment: impact on patients and carers
14.45-16.15, Auditorium 15
Educational financial support provided by Janssen Pharmaceutica NV

   
 C.06

Satellite Symposium
C.06 – Demystifying common issues in major depressive disorder: recognise and act!
14.45-16.15, Room C4
Educational financial support provided by Medscape Psychiatry (unrestricted grant from H. Lundbeck A/S)

   

Sunday 8 September

 CE.01 – Who is at risk of what? What we can learn from register data about patients with ADHD and their outcomes

 

Expert Science Exchange
CE.01 – Who is at risk of what? What we can learn from register data about patients with ADHD and their outcomes
09.00-10.00, Room C3
Financial support provided by MEDICE Arzneimittel

   
 CE.02 – Emotional functioning in major depressive disorder: unresolved symptom or side effect?

Expert Science Exchange
CE.02 – Emotional functioning in major depressive disorder: unresolved symptom or side effect? 
10.00-11.00, Room C2
Financial support provided by H. Lundbeck A/S


   
 IN.01 – Postpartum depression: how does it really feel?

Innovation Showcase
IN.01 – Postpartum depression: how does it really feel? 
12.00-12.30, The Bubble
Financial support provided by Sage Therapeutics, Inc.
 

   
 CE.03 – How do you approach the treatment of depressive episodes today? What pathways are thought to play a role in depression?

Expert Science Exchange
CE.03 – How do you approach the treatment of depressive episodes today? What pathways are thought to play a role in depression? 
15.15-16.15, Room C3
Financial support provided by Sage Therapeutics, Inc.

   
 C.07 – Are relapse prevention and functioning sufficiently prioritised in the treatment of schizophrenia?

 

Satellite Symposium
C.07 – Are relapse prevention and functioning sufficiently prioritised in the treatment of schizophrenia?
17:30 - 19:00, Hall A2
Educational financial support provided by H. Lundbeck A/S

 

   
 C.09 – Patient functioning in schizophrenia: can we change the burden?

Satellite Symposium
C.09 – Patient functioning in schizophrenia: can we change the burden?
17.30-19.00, Room C1
Educational financial support provided by Gedeon Richter Plc & RECORDATI S.p.A

   
  Satellite Symposium
C.12 – Major depressive disorder (MDD) treatment: from biological basis to patient reality
17.30-19.00, Room C4
Educational financial support provided by Janssen Pharmaceutica NV

Monday 9 September

   
CE.04 – How do you approach the treatment of depressive episodes today? What pathways are thought to play a role in depression? 

Expert Science Exchange
CE.04 – How do you approach the treatment of depressive episodes today? What pathways are thought to play a role in depression? 
09.00-10.00, Room C3
Financial support provided by Sage Therapeutics, Inc.

 

 

 
CE.05 – Targeting mental health disorders to reduce the burden of noncommunicable chronic diseases  

Expert Science Exchange
CE.05 – Targeting mental health disorders to reduce the burden of noncommunicable chronic diseases
10.00-11.00, Room C2
Financial support provided by Upjohn, A Pfizer Division

 

 IN.02 – Vortioxetine: a multimodal antidepressant for the treatment of major depressive disorder

Innovation Showcase
IN.02 – What can we expect from an antidepressant with a multimodal activity in the treatment of major depressive disorder?
12.00-12.30, The Bubble
Financial support provided by H. Lundbeck A/S

   
CE.06 – Discovering ADHD in adults 

Expert Science Exchange
CE.06 – Discovering ADHD in adults
15.15-16.15, Room C3
Financial support provided by Takeda


   
 CE.07 – Discovering ADHD in adults

Expert Science Exchange
CE.07 – Discovering ADHD in adults 
16.15-17.15, Room C3
Financial support provided by Takeda

 

   
 C.10 – Patient perspectives on treatment outcomes and goals in schizophrenia

Satellite Symposium
C.10 – Patient perspectives on treatment outcomes and goals in schizophrenia
17.30-19.00, Hall A2
Educational financial support provided by H. Lundbeck A/S

 

   
 

Satellite Symposium
C.11 – Transition in schizophrenia: symptoms, treatments and diagnosis - challenges from adolescence to adulthood 
17.30-19.00, Auditorium 15
Educational financial support provided by Sunovion Pharmaceuticals Inc., Sumitimo Dainippon Pharma Co. Ltd. and Angelini


Satellite Symposium (C)

These scientifically oriented sessions are organised by and with educational financial support from industry. The programmes have been reviewed for balance and rigour by the Scientific Programme Committee. These sessions might be accredited for European accreditation (CME) depending on the industry organising the satellite symposium.

Expert Science Exchange (CE)
The expert science exchange sessions provide the opportunity for focused, scientifically driven engagement between industry and a small group of participants.
Each session is 60 minutes and has a limited capacity of 80 participants. Admittance is given on a first-come-first-served basis. The sessions are organised and financially supported by industry. These sessions do not come with CME credits.

Innovation Showcase (INS)
These hands-on, interactive sessions provide a high-value forum for industry to engage with a small group of participants on a broad range of issues, including treatment approaches, the uses of specific medications, clinical insights, and product demonstrations. Each Innovation Showcase Session has a limited capacity. Admittance is given on a first-come-first-served basis. The sessions are organised and financially supported by industry. These sessions do not come with CME credits.

For the detailed programme, including abstracts and a short biography of most of the speakers, click here.